Last reviewed · How we verify
NCT07278544
Harnessing Communication Preferences
NA trial testing PrefFCT in Intellectual Disability in 60 participants. Currently enrolling.
31 March 2031
Quick facts
| Lead sponsor | Joel E. Ringdahl |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 15 August 2025 |
| Primary completion | 31 March 2031 |
| Estimated completion | 31 March 2031 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- PrefFCT
- NonPrefFCT
Conditions studied
- Intellectual Disability — all drugs for Intellectual Disability →
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
- Self-Injurious Behavior — all drugs for Self-Injurious Behavior →
- Communication Disabilities — all drugs for Communication Disabilities →
Sponsor
Joel E. Ringdahl
Who can join
Adults 2 to 90, any sex, with Intellectual Disability or Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate how preference for communication approach (e.g., using a touch talker versus picture cards) impacts treatment maintenance in the context of treatment to reduce challenging behavior exhibited by individuals with intellectual and/or developmental disabilities. As well, the clinical trial will evaluate how this preference impacts treatment relapse when care providers implement intervention and will identify potential demographic variables (e.g., age and symptom severity) that affect outcomes. The main question\[s\] it aims to answer \[is/are\]: Preferred communication strategies will persist to a greater extent when intervention is disrupted, relative to less preferred communication strategies. Communication modality preference will increase persistence for individuals with lower pre-experimental symptom severity scores and higher pre-experimental communication functioning scores. We predict demographic characteristics and developmental level will not impact intervention outcomes. Two groups will be compared. Group 1 will receive initial intervention using a preferred communication strategy. Group 2 will receive initial intervention using a non preferred, but effective, communication strategy. Intervention type will then be reversed. Researchers will compare preferred and non preferred interventions on continued expression of the communication strategy when intervention is challenged. Participants will exhibit alternative appropriate communicative behavior as a means of replacing/reducing challenging behavior. This will take place using (a) preferred communication strategies and (b) non preferred communication strategies. Following successful intervention with each type of communication, intervention will be challenged and continued use of the communication strategy will be measured.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07278544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intellectual Disability
Currently open trials in the same condition.
- NCT05473429 — Characterization of Nociception Phenotype in Individuals With Intellectual Disability · NA · recruiting
- NCT07497035 — Equine Therapy Programme on Stress, Autonomy and Balance in School-age Children With Intellectual Disabilities · NA · active not recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT06829264 — Testing an Evidence-Based Supported Employment Model in Autistic Young Adults · NA · recruiting
- NCT07476092 — Evaluation of the Effect of Digital-based Games on the Visual and Cognitive Performance of Young Children With Intellect · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07278544 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Joel E. Ringdahl
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07278544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing